Biological
MenACWY clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
GlaxoSmithKline (3) · University of Oxford (2) · LimmaTech Biologics AG (1)
Often tested with
Tested in the same studies.
4CMenB vaccine (2) · ChAdOx1 nCoV-19 (1) · Acetaminophen (1) · Meningococcal Vaccines (1)
Studies
Open first, then newest update. How each study uses MenACWY is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan InfantsCompletedPhase 1/2LimmaTech Biologics AGNCT04056117Written as MenACWY
- A Study of a Candidate COVID-19 Vaccine (COV001)CompletedPhase 1/2University of OxfordNCT04324606Written as MenACWY
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsCompletedPhase 3GlaxoSmithKlineNCT04502693Written as Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- A Sourcing Study to Collect Human Blood Samples From Healthy AdultsCompletedPhase 4GlaxoSmithKlineNCT03493919Written as Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- Evaluation of Antibody Persistence Following 4 MenACWY VaccinationsCompletedPhase 4GlaxoSmithKlineNCT02446691Written as MenACWY
- Understanding the Immune Response to Meningitis VaccinesCompletedPhase 3University of OxfordNCT00901940Written as Meningococcal (Groups A, C, Y and W-135) Conjugate
Given in every arm · 1 — MenACWY is usual care beside what is tested
As the comparator · 5 — what is tested is compared with MenACWY
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and InfantsCompletedPhase 2GlaxoSmithKlineNCT06213506Written as MenACWY
- Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.CompletedPhase 2LimmaTech Biologics AGNCT06523231Written as MenACWY
- Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-FiloCompletedPhase 3Janssen Vaccines & Prevention B.V.NCT02509494Written as MenACWY
- A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of AgeCompletedPhase 2GlaxoSmithKlineNCT03433482Written as MenACWY
- Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy AdolescentsCompletedPhase 2Novartis VaccinesNCT02140762Written as MenACWY
Codes
What other systems call MenACWY · ClinicalTrials.gg INT005208
- MeSH (NLM) C525703MenACWYOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C525703 | MenACWY | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.